Thus, in MM cases with heterogeneous expression of NKG2D ligands, immunotherapy with NKG2D-CAR-transduced cell products may lead to eradication of MM cells, even resistant cells with self-renewal potential [33]. Here, KLRK1 is linked to Miyoshi myopathy.